Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 3, 2015

Primary Completion Date

June 16, 2020

Study Completion Date

June 16, 2020

Conditions
Hematogenously Acquired Staphylococcus Aureus OsteomyelitisBone InfectionOsteomyelitis
Interventions
DRUG

Ceftaroline Fosamil

IV Ceftaroline fosamil 15 mg/kg (or 600 mg if \> 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour) for children 2 years of age - 17 years of age (inclusive). IV Ceftarloine Fosamil 10 mg/kg infused 120 (± 10) minutes q8h (± 1 hour) for children 1 years of age - less than 2 years of age (inclusive).

Trial Locations (1)

77030

Texas Children's Hospital, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Baylor College of Medicine

OTHER